Journal: Antibodies

Article Title: Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

doi: 10.3390/antib10010006

Figure Lengend Snippet: Folate receptor α (FOLR1) expression in breast cancer and non-small cell lung cancer (NSCLC) cell lines. ( a , b ) FOLR1 expression was determined by Western blot analysis in the breast cancer cell lines MCF7, T47D, MDA-MB-361, SK-BR-3, HCC1954, MDA-MB231, and BT549 and in the NSCLC cell lines PC-9, HCC827, NCI-H1650, HCC4006, NCI-H1975, PC-14, A549, NCI-H441, and ABC-1. Results were compared with those from normal human mammary epithelial cells (HMECs) and normal bronchial epithelial cells (BEAS-2B), respectively. Blots are representative of three independent experiments. ( c , d ) The cellular mRNA transcripts were quantified by real-time RT-PCR. Data are presented relative to HMEC values in breast cancer cell lines and BEAS-2B values in NSCLC cell lines, as means ± SEM ( n = 8); * p < 0.01.

Article Snippet: After washing with TBS-0.05% Tween, membranes were soaked with LuminataTM Crescendo Western HRP Substrate (Merck Millipore, Burlington, MA, USA) and visualized. β-actin was used as a loading control, and human FOLR1 transfected/overexpressed HEK293 cellular lysate was used as a positive control (Sino Biological Inc.; Wayne, PA, USA).

Techniques: Expressing, Western Blot, Quantitative RT-PCR

Journal: Antibodies

Article Title: Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

doi: 10.3390/antib10010006

Figure Lengend Snippet: FOLR1 attenuation decreases the effect of MORAb-202 on cell proliferation. ( a ) FOLR1 knockdown was determined by Western blot analysis. Lysates were subjected to immunoblot analysis using the indicated primary antibody. ( b , c ) T47D and HCC1954 cells, which are sensitive to MORAb-202, were transfected with NT siRNA or siRNA directed against FOLR1 . Transfected cells were reseeded in the presence or absence of the indicated concentration of MORAb-202. Data represent the means ± SEMs of the data obtained from for six replicated wells; * p < 0.01.

Article Snippet: After washing with TBS-0.05% Tween, membranes were soaked with LuminataTM Crescendo Western HRP Substrate (Merck Millipore, Burlington, MA, USA) and visualized. β-actin was used as a loading control, and human FOLR1 transfected/overexpressed HEK293 cellular lysate was used as a positive control (Sino Biological Inc.; Wayne, PA, USA).

Techniques: Western Blot, Transfection, Concentration Assay

Journal: Antibodies

Article Title: Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

doi: 10.3390/antib10010006

Figure Lengend Snippet: MORAb-202 inhibited the proliferation of MCF7 cells in co-culture with HCC1954 cells. ( a ) Schema of transwell co-culture system. ( b ) HCC1954 cells, which express FOLR1, were treated with or without 10 nM MORAb-202. Cells in the bottom well were stained with 0.005% crystal violet and counted. ( c ) MCF7 cells, which do not express FOLR1, were treated with or without 10 nM MORAb-202. Cells in the bottom well were stained with 0.005% crystal violet and counted. ( d ) MCF7 cells were plated in the bottom chamber of the 6-well plate, while HCC1954 cells were plated in the upper transwell permeable inserts with a membrane pore size of 1 μm, which fit into the 6-well culture plate. In this model, any potential bystander factors can diffuse through the permeable membrane. After 96 h of incubation with or without 10 nM MORAb-202, the cells in the bottom well (MCF7) were stained with 0.005% crystal violet and counted. Data represent the means ± SEMs, obtained from six replicate wells; * p < 0.01.

Article Snippet: After washing with TBS-0.05% Tween, membranes were soaked with LuminataTM Crescendo Western HRP Substrate (Merck Millipore, Burlington, MA, USA) and visualized. β-actin was used as a loading control, and human FOLR1 transfected/overexpressed HEK293 cellular lysate was used as a positive control (Sino Biological Inc.; Wayne, PA, USA).

Techniques: Co-Culture Assay, Staining, Incubation

Journal: Antibodies

Article Title: Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

doi: 10.3390/antib10010006

Figure Lengend Snippet: MORAb-202 suppressed orthotopic xenograft tumor growth of T47D cells. ( a ) T47D cells were orthotopically injected into the bilateral fourth mammary fat pad of NOD/SCID mice. Six mice were randomized into groups and intravenously treated with or without 5 mg/kg of MORAb-202. Tumors were measured twice weekly for 63 days. Data represent mean tumor volumes ± SEMs; * p < 0.01. ( b ) The representative T47D tumors after 63 days (the upper: the control, the lower: MORAb-202-treated tumor). ( c ) Body weight changes in non-obese diabetic/severe combined immune deficiency (NOD/SCID) mice over 63 days of treatment with PBS (control) and with MORAb-202 (5 mg/kg). ( d1 , d2 , e1 , e2 ) Seven days after PBS or MORAb-202 administration, the T47D tumor was stained with hematoxylin and eosin. Images were obtained at magnifications of 20× and 100×. The arrow indicates the peripheral tumor layer in e1 and e2 . ( d3 , d4 , e3 , e4 ) Seven days after PBS or MORAb-202 administration, FOLR1 was detected in paraffin-embedded T47D-derived tumor tissue by immunostaining at a magnification of 100× and 400×. ( f ) The sequence read of T47D tumor DNA in exon 6 TP53 and exons 9 and 20 PIK3CA.

Article Snippet: After washing with TBS-0.05% Tween, membranes were soaked with LuminataTM Crescendo Western HRP Substrate (Merck Millipore, Burlington, MA, USA) and visualized. β-actin was used as a loading control, and human FOLR1 transfected/overexpressed HEK293 cellular lysate was used as a positive control (Sino Biological Inc.; Wayne, PA, USA).

Techniques: Injection, Staining, Derivative Assay, Immunostaining, Sequencing

Journal: Antibodies

Article Title: Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

doi: 10.3390/antib10010006

Figure Lengend Snippet: MORAb-202 suppressed orthotopic xenograft tumor growth of MCF7 cells. ( a ) MCF7 cells were orthotopically injected into the bilateral fourth mammary fat pad of BALB/c-nu/nu nude mice. Six mice per group were randomized into groups and intravenously treated with or without 5 mg/kg of MORAb-202. Tumors were measured twice weekly for 32 days. Data in the figure represent mean tumor volumes ± SEMs; * p < 0.01. ( b ) The representative MCF7 tumors after 32 days (the upper: the control, the lower: MORAb-202-treated tumor). ( c ) Body weight changes in BALB/c-nu/nu nude mice over 32 days of treatment with PBS as control and with MORAb-202 5 mg/kg. ( d1 , d2 , e1 , e2 ) Seven days after PBS or MORAb-202 administration, the MCF7 tumor was stained with hematoxylin and eosin. The images were obtained at magnifications of 20× and 100×. The arrow indicates the peripheral tumor layer in e1 . ( d3 , d4 , e3 , e4 ) Seven days after PBS or MORAb-202 administration, FOLR1 was detected in paraffin-embedded MCF7-derived tumor tissue by immunostaining at a magnification 100× and 400×. ( f ) The sequence read of MCF7 tumor DNA in exon 6 TP53 and exons 9 and 20 PIK3CA.

Article Snippet: After washing with TBS-0.05% Tween, membranes were soaked with LuminataTM Crescendo Western HRP Substrate (Merck Millipore, Burlington, MA, USA) and visualized. β-actin was used as a loading control, and human FOLR1 transfected/overexpressed HEK293 cellular lysate was used as a positive control (Sino Biological Inc.; Wayne, PA, USA).

Techniques: Injection, Staining, Derivative Assay, Immunostaining, Sequencing

Journal: BMC Oral Health

Article Title: Folate-receptor 1 level in periodontal disease: a pilot study

doi: 10.1186/s12903-019-0909-z

Figure Lengend Snippet: The Spearman’s rank correlation (r) among clinical parameters and FOLR1 levels

Article Snippet: FOLR1 levels were assayed by Human FOLR1 kit (Boster, CA, USA) using enzyme-linked immune sorbent assay (ELISA) method.

Techniques: